https://prabadinews.com/

Email

weborders@prabadincorp.com

Call us

+1 (786)-332-3938
administrator
scd-protect-publication:-high-scd-risk-despite-modern-gdmt-across-19,500+-lifevest-patients Uncategorized
  • September 2, 2025

SCD-PROTECT publication: High SCD risk despite modern GDMT across 19,500+ LifeVest® patients

CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, is highlighting the recent European…
biofuture-2025-returns-to-new-york-city-october-13-15 Uncategorized
  • September 2, 2025

BioFuture 2025 Returns to New York City October 13-15

NEW YORK–(BUSINESS WIRE)– #biofuture2025–BioFuture 2025 Returns to New York City October 13-15
unlike-samsung-and-sk-hynix,-tsmc-discloses-loss-of-us-waiver-for-china Medical Supplies
  • September 2, 2025

Unlike Samsung and SK Hynix, TSMC discloses loss of US waiver for China

The United States has revoked Taiwan Semiconductor Manufacturing Co.’s (TSMC) authorization to ship equipment and materials without a license to…
rilzabrutinib-becomes-first-approved-btk-inhibitor-for-immune-thrombocytopenia Medical Supplies
  • September 2, 2025

Rilzabrutinib Becomes First Approved BTK Inhibitor for Immune Thrombocytopenia

Rilzabrutinib gained FDA approval as the first BTK inhibitor for chronic immune thrombocytopenia, offering new hope for patients with persistent…
orchard-corp.-appoints-james-cantrell-as-first-ceo-to-lead-strategic-growth Uncategorized
  • September 2, 2025

Orchard Corp. Appoints James Cantrell as First CEO to Lead Strategic Growth

CHICAGO–(BUSINESS WIRE)– #15Years–Orchard Corp. appoints James Cantrell as first CEO to drive growth in healthcare staffing as the company celebrates…
fda-approves-subcutaneous-lecanemab-injection-for-maintenance-dosing-in-early-alzheimer-disease Medical Supplies
  • September 2, 2025

FDA Approves Subcutaneous Lecanemab Injection for Maintenance Dosing in Early Alzheimer Disease

The subcutaneous injection for maintenance treatment enhances accessibility and reduces infusion time for patients.
mel-honey-us-–-709535-–-08/25/2025 Drug Test
  • September 2, 2025

Mel Honey US – 709535 – 08/25/2025

Unapproved New Drugs/Ophthalmic Drug Products
amneal-pharmaceuticals,-llc-–-709894-–-08/27/2025 Drug Test
  • September 2, 2025

Amneal Pharmaceuticals, LLC – 709894 – 08/27/2025

CGMP/Finished Pharmaceuticals/Adulterated
wisconsin-pharmacal-company,-llc-–-710329-–-08/22/2025 Drug Test
  • September 2, 2025

Wisconsin Pharmacal Company, LLC – 710329 – 08/22/2025

CGMP/Finished Pharmaceuticals/Adulterated
life-enthusiast-co-op-–-709315-–-08/25/2025 Drug Test
  • September 2, 2025

Life Enthusiast Co-op – 709315 – 08/25/2025

Unapproved New Drugs/Ophthalmic Drug Products